Key result
A hematologist and a cardiology specialist discuss the 2020 American Society of Hematology guidelines for managing pulmonary embolism, including catheter-directed thrombolysis and antithrombotic regimens.
Why the study?
Pulmonary embolism is acutely life-threatening and causes long-term complications, prompting discussion of updated 2020 American Society of Hematology guidelines in clinical context.
Discusses the application of the 2020 American Society of Hematology guidelines to the management of a patient with pulmonary embolism, including catheter-directed thrombolysis and antithrombotic regimens.
May aid PE management per 2020 ASH guidelines; leaves open CDT and antithrombotic regimen selection.
Pulmonary embolism can be acutely life-threatening and is associated with long-term consequences such as recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension. In 2020, the American Society of Hematology published updated guidelines on the management of patients with venous thromboembolism. Here, a hematologist and a cardiology and vascular medicine specialist discuss these guidelines in the context of the care of a patient with pulmonary embolism. They discuss advanced therapies such as catheter-directed thrombolysis in the short-term management of patients with intermediate-risk disease, recurrence risk stratification at presentation, and ideal antithrombotic regimens for patients whose pulmonary embolism was associated with a transient minor risk factor.
No takes yet. Share an insight, caveat, or question.
Kanjee et al. (2022) conducted a review in Pulmonary embolism. Management of pulmonary embolism was evaluated. A hematologist and a cardiology specialist discuss the 2020 American Society of Hematology guidelines for managing pulmonary embolism, including catheter-directed thrombolysis and antithrombotic regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: